Dr. Reddy's Laboratories Ltd
As of Oct 22, 2026, Dr. Reddy's Laboratories is in Stage 1, the basing phase, now in week 2 (since Oct 15, 2026). It closed at $13.23, 13.4% below its 52-week high and above its 200-day average, which is falling.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is RDY early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
RDY among Drug Manufacturers - Specialty & Generic36th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …36 | RDY | Stage 1 · wk 2 | 47 | +6.8% |
Dr. Reddy's Laboratories: quick answers
What stage is Dr. Reddy's Laboratories in?
As of Oct 22, 2026, Dr. Reddy's Laboratories (RDY) is in Stage 1, the basing phase. It entered Stage 1 on Oct 15, 2026 and is in week 2. What the four stages mean
Is Dr. Reddy's Laboratories in an uptrend?
Not yet. Dr. Reddy's Laboratories is in Stage 1, a base that can come before an uptrend. It trades 0.7% above its 200-day average, which is falling.
How far is Dr. Reddy's Laboratories from its 52-week high?
Dr. Reddy's Laboratories closed at $13.23 on Oct 22, 2026, 13.4% below its 52-week high of $15.27. Its 52-week low is $11.30.
How has Dr. Reddy's Laboratories performed over the past year?
As of Oct 22, 2026, Dr. Reddy's Laboratories is down 9.5% over the past year and down 3.9% so far in 2026.
Which sector and industry is Dr. Reddy's Laboratories in?
Dr. Reddy's Laboratories is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.